Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.
about
Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in miceMurine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.Murine immune response to Neisseria meningitidis group C capsular polysaccharide: analysis of monoclonal antibodies generated in response to a thymus-independent antigen and a thymus-dependent toxoid conjugate vaccineSerological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.Surface plasmon resonance analysis of antipolysaccharide antibody specificity: responses to meningococcal group C conjugate vaccines and bacteriaProtein carriers of conjugate vaccines: characteristics, development, and clinical trials.Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine.Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992.Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.Meningococcal group C conjugate vaccines.Mucosal immunogenicity of polysaccharides conjugated to a peptide or multiple-antigen peptide containing T- and B-cell epitopes.Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.PCR of peripheral blood for diagnosis of meningococcal diseaseSolution conformation and flexibility of capsular polysaccharides from Neisseria meningitidis and glycoconjugates with the tetanus toxoid protein.A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses.A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge modelVaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci.Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection.Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people.Bacterial Vaccine Antigen Discovery in the Reverse Vaccinology 2.0 Era: Progress and Challenges
P2860
Q24548847-60836714-38CC-4B05-A812-522DCC9DC0F4Q33767903-DB480977-BCF2-46FA-9949-BC068EB091CCQ34003052-5A01BD5B-8BEC-41A7-AD34-49BFC21AA185Q34006352-5DA77B1B-59C1-434A-A4F3-54C06E23E7AAQ34145007-D5091EBE-C91C-4158-9ED8-F43BB437D639Q34170021-3177A57B-617C-456E-96F2-C8FF89306EC4Q35013077-006CAEF5-814D-4630-B80D-1A13FF2461F3Q35224131-F54CB58D-1E0F-423A-A16D-35A532BF03FCQ35229074-7E54AFBC-FE14-4D1C-A9FC-70D0E797FA30Q35269816-A081D9E4-E43E-408F-9231-956A48DE59ECQ35423315-E021CEED-ADE5-41AB-966C-61A3602E66EBQ36154043-8D4048E0-A4F3-4127-A836-3F8C6F64E485Q36534641-B9E5D9AD-01AA-4DC6-B43D-B474DA751038Q37367010-D519D8AD-B86D-46D3-B792-775B27A96C5CQ39505800-63EFB2CF-84CA-4F78-9412-600E76EFF7A8Q39671989-D84DA571-C30F-4CAE-B10E-4A5B25E1915EQ40582738-A7750660-7408-4747-8D7A-4CE37CBE4C48Q41966979-9C6E3DE4-551D-4C1F-BE01-9D3C4E6CAE53Q43080129-F94E7797-A0C2-4124-B126-7B4AC5AD0EB7Q57817461-F637BF22-9E79-48FC-87BA-A382730EEDA6
P2860
Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.
description
1994 nî lūn-bûn
@nan
1994 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Safety and immunogenicity of m ...... e conjugate vaccine in adults.
@ast
Safety and immunogenicity of m ...... e conjugate vaccine in adults.
@en
Safety and immunogenicity of m ...... e conjugate vaccine in adults.
@nl
type
label
Safety and immunogenicity of m ...... e conjugate vaccine in adults.
@ast
Safety and immunogenicity of m ...... e conjugate vaccine in adults.
@en
Safety and immunogenicity of m ...... e conjugate vaccine in adults.
@nl
prefLabel
Safety and immunogenicity of m ...... e conjugate vaccine in adults.
@ast
Safety and immunogenicity of m ...... e conjugate vaccine in adults.
@en
Safety and immunogenicity of m ...... e conjugate vaccine in adults.
@nl
P2093
P2860
P1476
Safety and immunogenicity of m ...... de conjugate vaccine in adults
@en
P2093
D J Kennedy
E L Anderson
G M Carlone
R B Belshe
P2860
P304
P407
P577
1994-08-01T00:00:00Z